A Study of Enfuvirtide (Fuzeon) in Patients With Advanced Human Immunodeficiency Virus-1 (HIV-1) Infection
Status:
Completed
Trial end date:
2007-10-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety and tolerability of subcutaneous Fuzeon in patients with
advanced HIV-1 infection unable to construct an appropriate treatment regimen from currently
available antiretroviral agents. The anticipated time on study treatment is 3-12 months, and
the target sample size is 9 individuals.